BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33390784)

  • 1. Juniperus indica Bertol. extract synergized with cisplatin against melanoma cells via the suppression of AKT/mTOR and MAPK signaling and induction of cell apoptosis.
    Huang XF; Gao HW; Lee SC; Chang KF; Tang LT; Tsai NM
    Int J Med Sci; 2021; 18(1):157-168. PubMed ID: 33390784
    [No Abstract]   [Full Text] [Related]  

  • 2. Extract of
    Huang XF; Chang KF; Lee SC; Li CY; Liao HH; Hsieh MC; Tsai NM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32545807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of oral cancer by induction of cell cycle arrest and apoptosis using Juniperus communis extract.
    Lee CC; Hsiao CY; Lee SC; Huang XF; Chang KF; Lee MS; Hsieh MC; Tsai NM
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32856711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.
    Piotrowska A; Wierzbicka J; Rybarczyk A; Tuckey RC; Slominski AT; Żmijewski MA
    Int J Oncol; 2019 Apr; 54(4):1481-1495. PubMed ID: 30968156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
    Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
    Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
    Sinnberg T; Lasithiotakis K; Niessner H; Schittek B; Flaherty KT; Kulms D; Maczey E; Campos M; Gogel J; Garbe C; Meier F
    J Invest Dermatol; 2009 Jun; 129(6):1500-15. PubMed ID: 19078992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extract of
    Cui XL; Li KJ; Ren HX; Zhang YJ; Liu XD; Bu BG; Wang L
    World J Gastroenterol; 2019 Apr; 25(15):1854-1864. PubMed ID: 31057299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier.
    ; Tsai NM; Chang KF; Wang JC
    Cell Physiol Biochem; 2018; 49(6):2443-2462. PubMed ID: 30261501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyphyllin I Promoted Melanoma Cells Autophagy and Apoptosis via PI3K/Akt/mTOR Signaling Pathway.
    Long J; Pi X
    Biomed Res Int; 2020; 2020():5149417. PubMed ID: 32733943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Jiang S; Chang H; Deng S; Fan D
    Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Gao HW; Huang XF; Yang TP; Chang KF; Yeh LW; Hsieh MC; Weng JC; Tsai NM
    Am J Chin Med; 2019; 47(5):1171-1191. PubMed ID: 31315419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
    Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
    Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway.
    Zhou R; Chen H; Chen J; Chen X; Wen Y; Xu L
    BMC Complement Altern Med; 2018 Mar; 18(1):83. PubMed ID: 29523109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.